Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
HC Wainwright & Co. analyst Joseph Pantginis reiterates PDS Biotechnology (NASDAQ:PDSB) with a Buy and maintains $21 pri...
B. Riley Securities analyst Kalpit Patel maintains PDS Biotechnology (NASDAQ:PDSB) with a Buy and lowers the price target fr...
Majority of patients continue to be followed for survival with multiple patients approaching 3 years Median Overall Survival (m...
https://www.statnews.com/2024/05/16/pds-biotech-survival-benefit/ This is the online edition of Adam's Biotech Scorecard, a...
HC Wainwright & Co. analyst Joseph Pantginis reiterates PDS Biotechnology (NASDAQ:PDSB) with a Buy and maintains $21 pri...
PDS Biotechnology (NASDAQ:PDSB) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0...
HC Wainwright & Co. analyst Joseph Pantginis reiterates PDS Biotechnology (NASDAQ:PDSB) with a Buy and maintains $21 pri...
Cantor Fitzgerald analyst Louise Chen reiterates PDS Biotechnology (NASDAQ:PDSB) with a Overweight.
